bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer

Clinical and Experimental Metastasis

Volumn 17, Issue 7, 1999, Pages 545-554

  Koukourakis, Michael I ^e   Giatromanolaki, Alexandra ^a   O'Byrne, Keneth J ^b   Jiles, Cox ^b   Krammer, Barbara ^c   Gatter, Kevin C ^d   Harris, Adrian L ^d  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c UNIVERSITY OF SALZBURG   (Austria)

^d OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e Tumour and Angiogenesis Research Group Iraklion   (Greece)

Author keywords

Angiongenesis; bcl 2; c erB 2; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ONCOPROTEIN; PROTEIN BCL 2; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LIFE TABLES; LUNG NEOPLASMS; LYMPHOKINES; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; OBSERVER VARIATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THYMIDINE PHOSPHORYLASE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0000109509     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006780710148     Document Type: Article

References (39)

1. 1. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25.
2. 2. Ishikawa F, Miyazono K, Hellman U et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endathelial cell growth factor. Nature 1989; 338: 557-62.
3. 3. Bikfalvi A, Klein S, Pinticci G, Rifkin DB. Biological role of fibroblast growth factor-2. Endocr Rev 1996; 18: 26045.
4. 4. Takahashi Y, Bucana CD, Liu W et al. Platelet derived endothelial cell growth factor in human colon cancer angiogenesis: Role of infiltrating cells. J Natl Cancer Inst 1996; 88: 1146-51.
5. 5. Koukourakis MI, Giatromanolaki A, Kakolyris S et al. Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non small cell lung cancer. Impact on neoangiogenesis and survival. Br J Cancer 1998; 77: 1696-703.
6. 6. Dameron KN, Volpert O, Tainsk MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-4.
7. 7. Bouvet M, Ellis LM, Nishizaki M et al. Adenovirus-mediated wild type p53 gene transfer downregulates vascular endothelial growth factor expression and angiogenesis in human colon cancer. Cancer Rev 1998; 58: 2288-92.
8. 8. Giatromanolaki A, Koukourakis MI, Kakolyris S et al. Vascular endothelial growdi factor, wild-type p53 and angiogenesis in early operable non-small cell lung cancer. 1998; 4: 3017-24.
9. 9. Koukourakis MI, Giatromanolaki A, O'Byrne K et al. Platelet-Derived Endothelial Cell Growth Factor expression correlates with tumor angiogenesis and prognosis in non-small cell lung cancer. Br J Cancer 1997; 4: 477-81.
10. 10. Giatromanolaki A, Fountzilas G, Koukourakis MI et al. Neoangiogenesis in locally advanced squamous cell head and neck cancer correlates with thymidine phosphorylase expression and p53 nuclear oncoprotein accumulation. Clin Exp Metastasis 1998; 16: 665-72.
11. 11. Fontanini G, Boldrini L, Vignali S et al. Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma. Eur J Cancer 1998; 34: 718-23.
12. 12. Nakamura S, Akazawa K, Kinukawa N et al. Inverse correlation between the expression of bcl-2 and p53 proteins in primary gastric lymphoma. Hum Pathol 1996; 27: 225-33.
13. 13. Van Slooten HJ, Clahsen PC, Van Dierendonck et al. Expression of Bcl 2 in node negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br J Cancer 1996; 74: 78-85.
14. 14. Rak J, Mitsuhashi Y, Bayko L et al. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995; 55: 4575-80.
15. 15. Goldman CK, Kim J, Wong WL et al. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiform pathophysiology. Mol Biol Cell 1993; 4: 121-33.
16. 16. Gill J, Swerlick RA, Caughman SW. Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2 dependent DNA binding and transactivation. EMBO J 1997; 16: 750-9.
17. 17. Giatromanolaki A, Koukourakis MI, O'Byrne K et al. Non small cell lung cancer: C-erbB-2 correlates with low angiogenesis and poor prognosis. Anticancer Res 1996; 16: 3819-25.
18. 18. Koukourakis MI, Giatromanolaki A, O'Byrne K et al. Potential role of bcl-2 as a suppressor of tumor angiogenesis in non small cell lung cancer. Int J Cancer 1997; 74: 565-70.
19. 19. Mountain, CF. A new international staging system for lung cancer. Chest 1986; 89 (Suppl): 225-33.
20. 20. Giatromanolaki A, Koukourakis MI, Theodossiou D et al. Comparative evaluation of angiogenesis assessment with anti-Factor VIII and anti-CD31 immunostaining in non small cell lung cancer. Clin Cancer Res 1997; 3: 2493-500.
21. 21. Fox SB, Moghaddam A, Westwood M et al. Platelet derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues an immunohistochemical study. J Pathol 1995; 176: 183-90.
22. 22. Zhang L, Scott P, Turley H et al. Validation of anti-vascular endathelial growth factor (anti-VEGF) antibodies for immunohistochemical localisation of VEGF in tissue sections: Expression of VEGF in the human endometrium. J Pathol 1998; 185: 402-8.
23. 23. Guddo F, Giatromanolaki A, Koukourakis MI et al. MUC1 (Episialin) expression in non small cell lung cancer is independent of EGFR and c-erB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol 1998; 51: 667-71.
24. 24. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
25. 25. Cox DR. Regression models and life-tables. J R Stat Soc Series B 1972; 34: 187-220.
26. 26. Fontanini G, Vignati S, Lucchi M et al. Neoangiogenesis and p53 protein in lung cancer: Their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. Br J Cancer 1997; 75: 1295-301.
27. 27. Mattern J, Koomagi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumor cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996; 73: 931-4.
28. 28. Van Slooten HJ, Van de Vijver MJ, Van de Velde CJH et al. Loss of bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferation activity. Br J Cancer 1998; 77: 789-96.
29. 29. Kane DJ, Sarafin TA, Auton S et al. Bcl-2 inhibition of neural cell death: decreased generation of reactive oxygen species. Science 1993; 262: 1274-6.
30. 30. Hennet T, Bertoni G, Richter C, Peterhans E. Expression of bcl-2 protein enhences the survival of mouse fibrosarcoid cells in tumor necrosis factor mediated cytotoxicity. Cancer Res 1993; 53: 1456-60.
31. 31. Leek RD, Kaklamanis L, Pezzella F et al. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor negative tumours and in situ cancer. Br J Cancer 1994; 135-9.
32. 32. Pezzella F, Turley H, Kuzu I et al. bcl-2 protein in non small cell lung carcinoma. N Engl J Med 1993; 329: 690-4.
33. 33. Kanai Y, Ochiai A, Shibata T et al. c-erbB-2 gene product directly associates with beta-catenin and plakoglobin. Biochem Biophys Res Commun 1995; 208: 1067-72.
34. 34. Ochiai A, Akimoto S, Kanai Y et al. C-erbB-2 gene product associates with catenins in human cancer cells. Biochem Biophys Res Commun 1994; 205: 73-8.
35. 35. de-Porter CR, Eeckhout I, Schelfhout AM et al. Keratinocyte induced chemotaxis in the pathogenesis of Paget's disease of the breast. Histopathology 1994; 24: 349-56.
36. 36. Petit AM, Rak J, Hung MC et al. Neutralizing antibodies against epidermal growth faetor and ErbB-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151: 1523-30.
37. 37. Koukourakis MI, Giatromanolaki A, Kaklamanis L et al. c-erbB-2 and episialin challenge host immune response by HLA class I expression in human non-small cell lung cancer. J Immunother 1999; in press.
38. 38. Sgadari C, Angiolillo AL, and Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996; 87: 3877-82.
39. 39. Giatromanolald A, Koukourakis MI, Kaklamanis L et al. Focal thymidine phosphorylase expression associates with local neoangiogenesis and CD13 positive lymphocytic aggregation in non small cell lung cancer. Anticancer Res 1998; 18: 71-6.